The METHRO trials

Ali Hamaad, Muzahir Tayebjee, Gregory Lip

Research output: Contribution to journalReview article

8 Citations (Scopus)


Venous thromboembolism is a common and potentially fatal complication among hospital in-patients, particularly those undergoing orthopaedic surgery. Current prophylactic strategies utilise low molecular weight heparins (LMWHs) and warfarin. However, painful subcutaneous injections for LMWHs and delays in achieving target anticoagulation for warfarin pose significant problems clinically. The Melagatran for THRombin inhibition in Orthopaedic surgery (METHRO) trial represents a landmark step in the sequential combination of subcutaneous and oral anticoagulation with melagatran and ximelagatran, respectively, for surgical venous thromboprophylaxis. These agents have proven to be as effective and safe as LMWHs. Furthermore, with no need for dosage adjustment or therapeutic drug monitoring there is emerging evidence that ximelagatran may replace warfarin as the anticoagulant of choice.
Original languageEnglish
Pages (from-to)865-870
Number of pages6
JournalExpert opinion on investigational drugs
Issue number5
Publication statusPublished - 1 May 2003


  • surgery venous thromboembolism
  • ximelagatran
  • METHRO trials
  • melagatran


Dive into the research topics of 'The METHRO trials'. Together they form a unique fingerprint.

Cite this